114 related articles for article (PubMed ID: 32990946)
1. Evaluation of signal detection algorithms within the Elanco Animal Health Pharmacovigilance database.
Novotny MJ; Rhodes A; Shields J; Wilson A; Giraldo C; O'Gorman M; Real T; Sarsadskikh A; Wiseman S
J Vet Pharmacol Ther; 2021 Jan; 44(1):107-115. PubMed ID: 32990946
[TBL] [Abstract][Full Text] [Related]
2. Comparison of statistical signal detection methods within and across spontaneous reporting databases.
Candore G; Juhlin K; Manlik K; Thakrar B; Quarcoo N; Seabroke S; Wisniewski A; Slattery J
Drug Saf; 2015 Jun; 38(6):577-87. PubMed ID: 25899605
[TBL] [Abstract][Full Text] [Related]
3. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system.
Harpaz R; DuMouchel W; LePendu P; Bauer-Mehren A; Ryan P; Shah NH
Clin Pharmacol Ther; 2013 Jun; 93(6):539-46. PubMed ID: 23571771
[TBL] [Abstract][Full Text] [Related]
4. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
Caster O; Aoki Y; Gattepaille LM; Grundmark B
Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
[TBL] [Abstract][Full Text] [Related]
5. Exploring the impact of design criteria for reference sets on performance evaluation of signal detection algorithms: The case of drug-drug interactions.
Kontsioti E; Maskell S; Pirmohamed M
Pharmacoepidemiol Drug Saf; 2023 Aug; 32(8):832-844. PubMed ID: 36916014
[TBL] [Abstract][Full Text] [Related]
6. An Alternative to Disproportionality: A Frequency-Based Method for Pharmacovigilance Data Mining.
Jokinen JD; Lievano F; Scarazzini L; Truffa M
Ther Innov Regul Sci; 2018 May; 52(3):294-299. PubMed ID: 29714535
[TBL] [Abstract][Full Text] [Related]
7. Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank.
Caster O; Juhlin K; Watson S; Norén GN
Drug Saf; 2014 Aug; 37(8):617-28. PubMed ID: 25052742
[TBL] [Abstract][Full Text] [Related]
8. Drug Safety Monitoring in Children: Performance of Signal Detection Algorithms and Impact of Age Stratification.
Osokogu OU; Dodd C; Pacurariu A; Kaguelidou F; Weibel D; Sturkenboom MC
Drug Saf; 2016 Sep; 39(9):873-81. PubMed ID: 27255487
[TBL] [Abstract][Full Text] [Related]
9. Exploration of statistical shrinkage parameters of disproportionality methods in spontaneous reporting system of China.
Wang J; Ye XF; Guo XJ; Zhu TT; Qi N; Hou YF; Zhang TY; Shi WT; Wei X; Liu YZ; Wu GZ; He J
Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):962-70. PubMed ID: 26095121
[TBL] [Abstract][Full Text] [Related]
10. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
Zink RC; Huang Q; Zhang LY; Bao WJ
Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
[TBL] [Abstract][Full Text] [Related]
11. Benefits of combining change-point analysis with disproportionality analysis in pharmacovigilance signal detection.
Trinh NTH; Solé E; Benkebil M
Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):370-376. PubMed ID: 29992679
[TBL] [Abstract][Full Text] [Related]
12. The value of time-to-onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands.
Scholl JH; van Puijenbroek EP
Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1361-1367. PubMed ID: 27686554
[TBL] [Abstract][Full Text] [Related]
13. Criteria revision and performance comparison of three methods of signal detection applied to the spontaneous reporting database of a pharmaceutical manufacturer.
Matsushita Y; Kuroda Y; Niwa S; Sonehara S; Hamada C; Yoshimura I
Drug Saf; 2007; 30(8):715-26. PubMed ID: 17696584
[TBL] [Abstract][Full Text] [Related]
14. Use of measures of disproportionality in pharmacovigilance: three Dutch examples.
Egberts AC; Meyboom RH; van Puijenbroek EP
Drug Saf; 2002; 25(6):453-8. PubMed ID: 12071783
[TBL] [Abstract][Full Text] [Related]
15. Semantic distance-based creation of clusters of pharmacovigilance terms and their evaluation.
Dupuch M; Grabar N
J Biomed Inform; 2015 Apr; 54():174-85. PubMed ID: 25659451
[TBL] [Abstract][Full Text] [Related]
16. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
Berbain T; Pariente A; Miremont-Salamé G; Grandvuillemin A; Micallef J; Chouchana L; Benkebil M; Théophile H;
Drug Saf; 2020 Mar; 43(3):243-253. PubMed ID: 31974775
[TBL] [Abstract][Full Text] [Related]
17. A Feasibility Study of Drug-Drug Interaction Signal Detection in Regular Pharmacovigilance.
Hult S; Sartori D; Bergvall T; Hedfors Vidlin S; Grundmark B; Ellenius J; Norén GN
Drug Saf; 2020 Aug; 43(8):775-785. PubMed ID: 32681439
[TBL] [Abstract][Full Text] [Related]
18. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
Trippe ZA; Brendani B; Meier C; Lewis D
Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
[TBL] [Abstract][Full Text] [Related]
19. Validation of New Signal Detection Methods for Web Query Log Data Compared to Signal Detection Algorithms Used With FAERS.
Colilla S; Tov EY; Zhang L; Kurzinger ML; Tcherny-Lessenot S; Penfornis C; Jen S; Gonzalez DS; Caubel P; Welsh S; Juhaeri J
Drug Saf; 2017 May; 40(5):399-408. PubMed ID: 28155198
[TBL] [Abstract][Full Text] [Related]
20. Increased risk for aseptic meningitis after amoxicillin or amoxicillin-clavulanic acid in males: A signal revealed by subset disproportionality analysis within a global database of suspected adverse drug reactions.
Chandler RE
Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):389-395. PubMed ID: 30556617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
